Billiontoone Inc Cl A BLLN

https://www.marketbeat.com/earnings/reports/2026-11-4-billiontoone-inc-stock/ $BLLN Billiontoone Earnings Transcript

$BLLN Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.32 up 220.00% YoY • Reported revenue of $122.98M up 47.25% YoY • BillionToOne raised full year 2026 revenue guidance to $460M to $470M, representing 51% to 54% growth compared to full year 2025, from previous guidance of $450M to $465M.

$BLLN reports quarterly results after the close Wed Nov 4, consensus EPS $0.30 / revenue $116M. Conference call 4:30 PM ET Wed Nov 4: https://investors.billiontoone.com/events/event-details/billiontoone-3q26-earnings-call Shares trade at $111.06, above the 50-day SMA ($104.40) and above the 200-day ($96.63), near the top of the 20-day range ($90.48–$119.20). EMA 20 $107.94, daily RSI 56. Analyst consensus target $129.00 (7 analysts). Interactive chart with bull and bear scenarios on JC Just Charts: https://justcharts.merlintrader.com/#BLLN Not investment advice. Hub: https://www.merlintrader.com/billiontoone-blln-stock-hub/

$BLLN Q3 2026 results call: Wed Nov 4, 4:30 p.m. ET (scheduled, per company release). Chart: last close $114.84 (Oct 29). Above the 20-day EMA, 50-day SMA, 200-day SMA (EMA20 $106.68, SMA50 $103.45, SMA200 $96.34). RSI(14) 62. 20-day range $90.48-$119.20. Webcast: https://investors.billiontoone.com/news-events/events-presentations Hub: https://www.merlintrader.com/billiontoone-blln-stock-hub/

$BLLN I discovered this company in my analysis of $NTRA and thought it looked interesting. Read why I've given this a buy rating, suspecting it will come to take market share versus Natera soon: https://seekingalpha.com/article/4959531-billiontoone-new-kid-on-the-molecular-diagnostics-block-poised-to-take-share

$BLLN MAY BE DEPENDENT ON NOW BANNED SUPPLIERS On Oct 28, DHS issued import guidance that "Blocks Chinese Genomics Companies Linked to Forced Labor," namely BGI and MGI. BGI, MGI, and Complete Genomics are interrelated Chinese companies that produce DNBSeq, a sequencing platform. I've heard, but cannot independently verify, that $BLLN uses DNBSeq in its labs. They disclose a risk in their latest 10-K: "While we may currently rely, or in the future may rely, on equipment, reagents, or laboratory services from one or more companies that could, in the future, be designated as “biotechnology companies of concern” under this or similar legislation, we have undertaken and continue to undertake measures to mitigate the risks associated with utilizing material from biotechnology companies of concern." They say supplier disruptions "could require that we revalidate our tests." I may be short. Sources: DHS ban: https://www.dhs.gov/news/2026/10/28/under-president-trump-dhs-blocks-chinese-genomics-companies-linked-forced-labor 10-K: https://www.sec.gov/Archives/edgar/data/2070849/000207084926000017/blln-20251231.htm

$BLLN rose 2.0% to $107.77, above the 50-day EMA ($104.35) and the 200-day ($98.07), mid-way through a wide 20-day range of $90.48-$125.00. Daily RSI 55. Interactive chart at JC Just Charts: https://justcharts.merlintrader.com/#BLLN Not investment advice.

$BLLN Latest company news, October 14, 2026: BillionToOne $BLLN will report Q3 2026 results on November 4 after the close. On October 7 a peer-reviewed study showed its tissue-free Northstar Response matched a tumor-informed assay on the direction of ctDNA changes in 67 of 71 cases. Full hub (prenatal and oncology testing, cash, insider sales): https://www.merlintrader.com/billiontoone-blln-stock-hub/ Not investment advice.